Advertisement

Clinical studies with anastrozole

  • Anthony Howell
  • Alan Wakeling
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

Oestrogens play a dominant role in controlling the growth of many breast cancers [1, 2]. The ovaries are the primary source of oestrogen in premenopausal women but ovarian oestrogen production diminishes with age. In postmenopausal women, oestrogens are synthesised by the aromatisation of androgen precursors in the skin, muscle, adipose and breast tissue, including malignant breast tumours [3]. Oestrogen action is inhibited by blocking the oestrogen receptor (ER) with antioestrogens such as tamoxifen, by ovarian ablation using surgery, radiotherapy or luteinising hormone-releasing hormone analogs such as goserelin, or, in postmenopausal women, by blocking oestrogen production by inhibiting aromatase activity [4].

Keywords

Breast Cancer Postmenopausal Woman Aromatase Inhibitor Advanced Breast Cancer Early Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chen S (1998) Aromatase and breast cancer. Front Biosci 3: d922–d933PubMedGoogle Scholar
  2. 2.
    Wakeling AE (1990) Mechanisms of growth regulation of human breast cancer. Baillieres Clin Endocrinol Metab 4: 51–66PubMedCrossRefGoogle Scholar
  3. 3.
    Simpson ER, Dowsett M (2002) Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 57: 317–338PubMedCrossRefGoogle Scholar
  4. 4.
    Howell A, Dowsett M (1997) Recent advances in endocrine therapy of breast cancer. BMJ 315: 863–866PubMedGoogle Scholar
  5. 5.
    Gruber CJ, Tschugguel W, Schneeberger C, Huber JC (2002) Production and actions of estrogens. N Engl J Med 346: 340–352PubMedCrossRefGoogle Scholar
  6. 6.
    Santen RJ, Santner S, Davis B,Veldhuis J, Samojlik E, Ruby E (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47: 1257–1265PubMedCrossRefGoogle Scholar
  7. 7.
    Coombes RC (1998) Aromatase inhibitors and their use in the adjuvant setting. Recent Results Cancer Res 152: 277–284PubMedGoogle Scholar
  8. 8.
    Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, Cummings FJ (1994) Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73: 354–361PubMedCrossRefGoogle Scholar
  9. 9.
    Lipton A, Santen RJ (1974) Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33: 503–512PubMedCrossRefGoogle Scholar
  10. 10.
    Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AM, Gazet JC, Coombes RC (1986) Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 46: 4823–4826PubMedGoogle Scholar
  11. 11.
    Wiseman LR, McTavish D (1993) Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Drugs 45: 66–84PubMedCrossRefGoogle Scholar
  12. 12.
    Perez-Carrion R, Alberola Candel V, Calabresi F (1996) Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5Suppl 7: S19–S24Google Scholar
  13. 13.
    Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348: 2431–2442PubMedCrossRefGoogle Scholar
  14. 14.
    Dukes M, Edwards PN, Large M, Smith IK, Boyle T (1996) The preclinical pharmacology of “Arimidex” (anastrozole; ZD1033)-a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 58: 439–44PubMedCrossRefGoogle Scholar
  15. 15.
    Plourde PV, Dyroff M, Dukes M (1994) Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30: 103–111PubMedCrossRefGoogle Scholar
  16. 16.
    Grimm SW, Dyroff MC (1997) Inhibition of human drug metabolizing cytochromes p450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 25: 598–602PubMedGoogle Scholar
  17. 17.
    Hozumi Y, Hakamata Y, Sasanuma H, Ogura S, Nagai H (2002) Effects of anastrozole on lipid metabolism compared with tamoxifen in rats. Breast Cancer Res Treat 76: 131–136PubMedCrossRefGoogle Scholar
  18. 18.
    Yue W, Zhou D, Chen S, Brodie A (1994) A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54: 5092–5095PubMedGoogle Scholar
  19. 19.
    Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A (1999) The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 57: 183–192PubMedCrossRefGoogle Scholar
  20. 20.
    Dukes M (1997) The relevance of preclinical models to the treatment of postmenopausal breast cancer. Oncology 54(Suppl 2): 6–10PubMedCrossRefGoogle Scholar
  21. 21.
    Plourde PV, Dyroff M, Dowsett M (1995) Arimidex: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 53: 175–179PubMedCrossRefGoogle Scholar
  22. 22.
    Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ (1996) Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73: 543–548PubMedGoogle Scholar
  23. 23.
    Vorobiof DA, Kleeberg UR, Perez-Carrion R, Dodwell DJ, Robertson JF, Calvo L, Dowsett M, Clack G (1999) A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer. Ann Oncol 10: 1219–1225PubMedCrossRefGoogle Scholar
  24. 24.
    Dowsett M, Donaldson K, Tsuboi M, Wong J, Yates R (2000) Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. Cancer Chemother Pharmacol 46: 35–39PubMedCrossRefGoogle Scholar
  25. 25.
    Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lønning PE (1996) Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74: 1286–1291PubMedGoogle Scholar
  26. 26.
    Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20: 751–757PubMedCrossRefGoogle Scholar
  27. 27.
    Sainsbury R (2004) Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br J Cancer 90: 1733–1739PubMedGoogle Scholar
  28. 28.
    Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G et al. (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39: 2318–2327PubMedCrossRefGoogle Scholar
  29. 29.
    Fishman J, Nisselbaum JS, Menendez-Botet CJ, Schwartz MK (1977) Estrone and estradiol content in human breast tumors: relationship to estradiol receptors. J Steroid Biochem 8: 893–896PubMedCrossRefGoogle Scholar
  30. 30.
    Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81: 1460–1464PubMedCrossRefGoogle Scholar
  31. 31.
    Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC (1986) Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 22: 515–525PubMedCrossRefGoogle Scholar
  32. 32.
    van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH (1985) Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue. Cancer Res 45: 2907–2912PubMedGoogle Scholar
  33. 33.
    Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86: 245–253PubMedCrossRefGoogle Scholar
  34. 34.
    Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjorn B, Dowsett M, Einstein LP (2001) Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 7: 1230–1236PubMedGoogle Scholar
  35. 35.
    Dowsett M, Yates R, Wong Y and on behalf of the Arimidex Study Group (1998) ‘Arimidex’ (anastrozole): lack of interactions with tamoxifen, antipyrine, cimetidine and warfarin. Eur J Cancer 34: S39–S40CrossRefGoogle Scholar
  36. 36.
    Yates RA, Wong J, Seiberling M, Merz M, Marz W, Nauck M (2001) The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 51: 429–435PubMedCrossRefGoogle Scholar
  37. 37.
    Dowsett M, Tobias JS, Howell A, Blackman GM, Welch H, King N, Ponzone R, von Euler M, Baum M (1999) The effect of anastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer. Br J Cancer 79: 311–315PubMedGoogle Scholar
  38. 38.
    Dowsett M, Cuzick J, Howell A, Jackson I (2001) Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex’, Tamoxifen Alone or in Combination’ (ATAC) trial. Br J Cancer 85: 317–324PubMedCrossRefGoogle Scholar
  39. 39.
    Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79: 730–739PubMedCrossRefGoogle Scholar
  40. 40.
    Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R et al. (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A: 404–412PubMedCrossRefGoogle Scholar
  41. 41.
    Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A et al. (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14: 2000–2011PubMedGoogle Scholar
  42. 42.
    Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A et al. (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83: 1142–1152PubMedCrossRefGoogle Scholar
  43. 43.
    Howell A, Robertson JF, Vergote I (2003) A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 82: 215–222PubMedCrossRefGoogle Scholar
  44. 44.
    Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758–3767PubMedGoogle Scholar
  45. 45.
    Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18: 3748–3757PubMedGoogle Scholar
  46. 46.
    Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee et al. (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92: 2247–2258PubMedCrossRefGoogle Scholar
  47. 47.
    Nabholtz JM, Bonneterre J, Buzdar A, Robertson JFR, Thürlimann B, for the Arimidex Writing Committee on behalf of the Investigators (2003) Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39: 1684–1689PubMedCrossRefGoogle Scholar
  48. 48.
    Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, Casanovas J, Puig-Gali M (2003) Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 26: 317–322PubMedCrossRefGoogle Scholar
  49. 49.
    Thürlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J, Arimidex Study Group (2003) Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39: 2310–2317PubMedCrossRefGoogle Scholar
  50. 50.
    Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochiltz C, Goldhirsch A et al. (2004) Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95 — a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 85: 247–25PubMedCrossRefGoogle Scholar
  51. 51.
    ATAC_Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131–2139CrossRefGoogle Scholar
  52. 52.
    ATAC Trialists’ Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98: 1802–1810CrossRefGoogle Scholar
  53. 53.
    ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365: 60–62CrossRefGoogle Scholar
  54. 54.
    Buzdar AU (2006) Anastrozole for breast cancer: recent advances and ongoing challenges. Expert Rev Anticancer Ther 6: 839–848PubMedCrossRefGoogle Scholar
  55. 55.
    The ATAC Trialists’ Group (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7: 633–643CrossRefGoogle Scholar
  56. 56.
    Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H et al. (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455–462PubMedCrossRefGoogle Scholar
  57. 57.
    Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2 years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 1: 2664–2670CrossRefGoogle Scholar
  58. 58.
    Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C et al. (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17Suppl 7: vii10–vii14PubMedCrossRefGoogle Scholar
  59. 59.
    Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R (2006) Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7: 991–996PubMedCrossRefGoogle Scholar
  60. 60.
    Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR (2000) The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6: 2229–2235PubMedGoogle Scholar
  61. 61.
    Milla-Santos A, Milla L, Calvo N, Portella J, Rallo L, Casanovas J, Pons M (2003) Anastrozole is an effective neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer irrespective of cerbB2. Proc Am Soc Clin Oncol 22: 39Google Scholar
  62. 62.
    Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR (2002) Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 87: 334–338PubMedCrossRefGoogle Scholar
  63. 63.
    Semiglazov VF, Semiglazov VV, Ivanov VG, Ziltsova EK, Dashyan GA, Kletzel A, Bozhok AA, Nurgaziev KS, Tzyrlina EV, Berstein LM (2003) Anastrozole (A) vs tamoxifen (T) vs combine (A + T) as neoadjuvant endocrine therapy of postmenopausal breast cancer patients. Proc Am Soc Clin Oncol 22: 880Google Scholar
  64. 64.
    Milla-Santos A, Milla L, Calvo N, Portella J, Rallo L, Casanovas JM, Pons M, Rodes J (2004) Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer. Anticancer Res 24: 1315–1318PubMedGoogle Scholar
  65. 65.
    Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G et al. (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23: 5108–5816PubMedCrossRefGoogle Scholar
  66. 66.
    Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer 106: 2095–210PubMedCrossRefGoogle Scholar
  67. 67.
    Smith I, Cataliotti L (2004) Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women: the IMPACT and PROACT trials. Eur J Cancer Suppl 2: 69Google Scholar
  68. 68.
    Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators (2007) Long-term results of tamoxifen prophylaxis for breast cancer — 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99: 272–282PubMedCrossRefGoogle Scholar
  69. 69.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388PubMedCrossRefGoogle Scholar
  70. 70.
    Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296–300PubMedCrossRefGoogle Scholar
  71. 71.
    Cuzick J (2003) Aromatase inhibitors in prevention — data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163: 96–103PubMedGoogle Scholar
  72. 72.
    Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467CrossRefGoogle Scholar
  73. 73.
    Sawada S, Sato K (2003) Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer. Breast Cancer Res Treat 82Suppl 1: S31–S32Google Scholar
  74. 74.
    Wojtacki J, Lesniewski-Kmak K, Piotrowska M, Rolka-Stempniewicz G, Kubik M, Wroblewska M (2004) Effect of anastrozole on serum levels of apolipoprotein A-I and B in patients with early breast cancer: additional data on lack of atherogenic properties. Breast Cancer Res Treat 88: S238Google Scholar
  75. 75.
    Wojtacki J, Lesniewski-Kmak K, Pawlak W, Nowicka E (2004) Anastrozole therapy and lipid profile: an update. Eur J Cancer Suppl 2: 142Google Scholar
  76. 76.
    Wojtacki J, Lesniewski-Kmak K, Kruszewski WJ (2002) Anastrozole therapy does not compromise lipid metabolism in breast cancer patients previously treated with tamoxifen. Breast Cancer Res Treat 76Suppl 1: S75Google Scholar
  77. 77.
    Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 58–66PubMedCrossRefGoogle Scholar
  78. 78.
    Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, Banzer D, Benevolenskaya LI, Bhalla A, Bruges AJ et al. (2002) Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study. Osteoporos Int 13: 565–571PubMedCrossRefGoogle Scholar
  79. 79.
    van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29: 517–522PubMedCrossRefGoogle Scholar
  80. 80.
    Writing Group for the Women’s Health Initiative (WHI) Investigators (2002) Risks and benefits of estrogen and progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized trial. J Am Med Assoc 288: 321–333CrossRefGoogle Scholar
  81. 81.
    Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J et al. (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23: 619–629PubMedCrossRefGoogle Scholar
  82. 82.
    Van Poznak C, Hannon RA, Clack G, Campone M, Mackey JR, Apffelstaedt J, Eastell R, on behalf of the SABRE investigators (2006) The SABRE study: effects of risedronate on bone mineral density and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer — first results. Breast Cancer Research and Treatment vol 100(Suppl 1), abs 4061Google Scholar
  83. 83.
    Jonat W, Hilpert F, Kaufmann M (2007) Aromatase inhibitors: a safety comparison. Expert Opin Drug Saf 6: 165–174PubMedCrossRefGoogle Scholar
  84. 84.
    Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738–2746PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • Anthony Howell
    • 1
  • Alan Wakeling
    • 2
  1. 1.CRUK Department of Medical OncologyChristie Hospital NHS TrustManchesterUK
  2. 2.Department of Cancer and Infection ResearchAstraZeneca PharmaceuticalsMacclesfieldUK

Personalised recommendations